Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970462 · ClinicalTrials.gov registry record · Phase 4
Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
A Phase 4 study, sponsored by Kathleen Dungan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01970462: Clinical Trial Phase 4 study, sponsored by Kathleen Dungan.
NCT01970462 is a Phase 4 study that was terminated before completion, run by Kathleen Dungan. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01970462, a Phase 4 study, was terminated before completion, sponsored by Kathleen Dungan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient population due to the effects on hepatic glucose production (a major feature of SH), safety (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and tolerability. The secondary objective of this study is to determine whether the management of patients with persistent insulin requirements following cardiac surgery differs among patients with stress hyperglycemia or mild diabetes.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970462
The ClinicalTrials.gov registry entry for NCT01970462 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathleen Dungan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01970462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970462 about?
NCT01970462 is a clinical study titled "Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery". This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient population due to the effects...
What is the current status of trial NCT01970462?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2014-01. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01970462?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01970462?
This trial is sponsored by Kathleen Dungan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.